Stelara denials in California external review
In the California DMHC record, independent physician reviewers decided 57 published external-review cases involving Stelaraand overturned the plan’s denial in 80.7%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
By condition
| Condition | Decisions | Overturned |
|---|---|---|
| Crohn's Disease | 24 | 87.5% |
| Ulcerative Colitis | 12 | 91.7% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 52 | 80.8% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 5 | 80% |
What the reviewers wrote
Where the denial was overturned
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The parents of the patient requested authorization and coverage for Stelara (ustekinumab) one-time induction dose of 260 mg administered by intravenous infusion and the administration of the Stelara infusion at a hospital-based outpatient infusion center.Government regulations have approved Stelara for the treatment of Crohn's disease and ulcerative colitis in adults. A review of medical literature supports the efficacy and safety of Stelara in children with inflammatory bowel disease. In a study, the authors found that Stelara is efficacious and safe in pediatric patients with inflammatory bowel disease. Further, Stelara has proven to be efficient in pediatric patients resistant to anti-tumor necrosis factor (TNF) medications.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Stelara every 28 days (or every four weeks). The U.S. Food and Drug Administration (FDA) approves the use of Stelara for the treatment of Crohn's disease and ulcerative colitis in adults. While Stelara lacks FDA approval for use in pediatric patients, current medical literature supports the efficacy and safety of Stelara for the treatment of children with inflammatory bowel disease. Researchers state, “Ustekinumab is efficacious and safe in pediatric patients with inflammatory bowel disease.” In a multicenter retrospective cohort study, researchers report that subcutaneous ustekinumab should be considered a viable therapeutic option for pediatric patients who are refractory to other biological agents.
Where the denial was upheld
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The parents of the patient requested authorization and coverage for Stelara 260 mg.The government has approved Stelara for the treatment of ulcerative colitis in adults. In a study, the authors found that Stelara is efficacious and safe in pediatric patients with inflammatory bowel disease. Further, Stelara has proven to be efficient in pediatric patients resistant to anti-tumor necrosis factor (TNF) medications. The study also revealed that patients’ Pediatric Crohn's Disease Activity Index (PCDAI) has been significantly improved in patients with severe disease treated with Stelara. In another study, the authors of a study indicated that Stelara demonstrated efficacy in pediatric patients with otherwise treatment-refractory UC.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Stelara injections for treatment of the enrollee who has a history of severe plaque psoriasis. Findings: The physician reviewer found that the documentation provided does not support the medical necessity for the requested medication in this clinical setting. Due to the location of the psoriatic plaques, phototherapy is also not practical as penetration of the ultraviolet light is difficult in those areas. Due to her age and child-bearing status, use of acitretin is also not recommended. The provider noted that due to the patient’s history of malignancy, the patient is precluded from methotrexate, cyclosporine and tumor necrosis factor (TNF) inhibitors. However, the medication requested is also an injectable biologic agent.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
Why plans deny Stelara — and what reviewed cases show
Stelara (ustekinumab) is FDA-approved for: crohn's disease (adults); ulcerative colitis (adults); plaque psoriasis and psoriatic arthritis. An on-label indication can be important evidence when a denial frames the requested use as unproven or cosmetic.
Biosimilar and formulary switching
Ustekinumab biosimilars — including an FDA-designated interchangeable — are now on formularies, and plans are moving patients off brand Stelara. If you're stable, the exception question is whether a switch risks your remission; if you're starting fresh, expect the plan to steer to its preferred product.
Dose-interval escalation denied
Gastroenterologists sometimes shorten Stelara's maintenance interval when disease activity returns before the next scheduled dose. Plans deny the extra doses as exceeding quantity limits. This is a prescriber-judgment fight: response history and drug-level or inflammatory-marker documentation carry it.
Step therapy behind TNF blockers
Formularies frequently require TNF-blocker failure before an IL-12/23 agent. Documented prior biologic history — or the clinical reasons a TNF blocker is wrong for you — is the standard exception ground.
Both step-therapy and quantity-limit denials route through the formulary exception process: the prescriber's supporting statement about your prior treatment and clinical needs triggers short mandatory decision deadlines.
Evidence cited in overturned Stelara decisions
- Document the full biologic history: what was tried, how long, and why it stopped working or couldn't be used.
- For interval-escalation denials, have the prescriber connect the requested regimen to your documented disease activity — this is dosing judgment, not experimental use of the drug.
- If the plan is forcing a switch mid-remission, make the risk of relapse the centerpiece and demand the clinical basis for interrupting stable therapy.
- Request the exact criteria and the reviewer's specialty; IBD dosing decisions reviewed without gastroenterology input are challengeable on that basis.
The published California record contains 57 external-review decisions involving Stelara; 80.7% were overturned. This historical rate does not predict another case. For the full class-wide picture — step therapy, biosimilar switching, dose caps, and the record for every IBD biologic — see the Crohn’s & colitis biologic appeal guide.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Stelara, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY